The purpose of this study is to see if it is safe and effective to give T-20 to HIV-positive adults. T-20 is an anti-HIV drug.
Patients are randomly placed into 1 of 6 groups: 4 dose levels of T-20 are given by subcutaneous infusion and 2 by subcutaneous injection. The entire study lasts 7 weeks; including a 2-week screening period, followed by 28 days of treatment and 1 week of follow-up.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Enrollment
78
Univ of Alabama at Birmingham / 1917 AIDS O/P Cln
Birmingham, Alabama, United States
UCLA School of Medicine / Ctr for Research and Education
Los Angeles, California, United States
San Francisco Gen Hosp
San Francisco, California, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Quest Clinical Research
San Francisco, California, United States
IDC Research Initiative
Altamonte Springs, Florida, United States
Northwestern Univ / Infect Dis Div / Pasavant Pav 828
Chicago, Illinois, United States
Johns Hopkins Hosp
Baltimore, Maryland, United States
CRI of New England
Brookline, Massachusetts, United States
NYU Med Ctr / C & D Building
New York, New York, United States
Univ North Carolina at Chapel Hill / Dept of Medicine
Chapel Hill, North Carolina, United States
...and 1 more locations